Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
AlopeciaBreast CancerPersistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.
Hair Up Prospective Study
Hair LossThe objective of this study is to assess the performance of Hair Up on female pattern hair shedding and regrowth. 58 adult female patients suffering from hair loss will be evaluated in a single center prospective study
Topical Crisaborole in Patients With Alopecia Areata
Alopecia AreataThe aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.
Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling
Alopecia AreataThe investigators propose to study the efficacy of micro-needling via the SOL Nova Device in generating hair growth in patients with Alopecia Areta (AA) who are either non-responsive or only partially responsive to combination oral JAK inhibitor plus oral minoxidil therapy.
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With...
AlopeciaAnxiety11 moreThis clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
AlopeciaChemotherapy EffectsWe would suggest to conduct "VOLUME-2" study, as an extension of the ongoing "VOLUME" study with all subjects already included. After completion of VOLUME study, the study will be directly extend with an "open-label design". All participants, who agreed to pursue, with either "Placebo" or "CG428", will receive CG428 treatment for an additional six-month period. VOLUME-2 study would be ideal and timely by enabling no interruption of product use. The Primary Objective is to observe for a longer period the efficacy of CG428 (12 months : 6months Volume + 6 months Volume-2) in order to better discriminate later or non-responder populations. Secondary Objectives are : Evaluate how far CG428 can improve hair-pattern (reach a plateau or constant progression) Evaluate motivation and adherence of subjects Long term safety
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With...
Androgenetic AlopeciaThis study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).
Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia AreataThe purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and therapeutic aspects, suggest that alefacept, which has been shown to be a safe and statistically significant beneficial therapeutic modality for the treatment of psoriasis, may have therapeutic value in alopecia areata.
A Clinical Study to Assess the Safety and Effectiveness of Plant Based Biotin in Healthy Human Subjects...
Hair ThinningHair Brittle1 moreThis is a randomized, placebo-controlled, double-blind, two-arm, single-centre, proof-of-concept, clinical study to evaluate the safety and efficacy of Plant based Biotin in Healthy Human Subjects with thin, dry, and brittle hair. a sufficient number (maximum of 54 (27/arm)) of female/male adult subjects were recruited/enrolled to ensure a total of 50 subjects (25 subjects/arm) completed the study.
The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia...
Androgenic AlopeciaThis randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. A total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks.